Maryland Tech Council Warns Drug Reimbursement Plan Risks Patient Access

Maryland lawmakers are advancing a plan that would tether the state’s drug reimbursement rates to Medicare’s negotiated prices, a move the Maryland Tech Council warns could disrupt patient access without lowering out-of-pocket costs at the pharmacy counter.

The proposal directs the state’s Prescription Drug Affordability Board to use Medicare’s Maximum Fair Price as the Upper Payment Limit for 20 medications in state health plans. Medicare’s Drug Price Negotiation Program, established under the Inflation Reduction Act, allows the federal government to set prices for select drugs covered by Medicare. Maryland now wants to import those federal benchmarks into state-regulated markets.

“When removed from Medicare’s statutory framework, MFP functions as a reimbursement ceiling with the same access consequences as any other Upper Payment Limit,” the Rare Access Action Project explains in its analysis of the proposal.

The council argues the mechanics are mismatched. The federal government is the nation's largest drug purchaser, using its legal authority and budget power to require manufacturers to take part. States lack that authority. Manufacturers can decline to participate in a state price-capping plan without exiting the national market, leaving the state’s reimbursement cap as a ceiling that pharmacies and providers cannot breach.

In response, insurers and pharmacy benefit managers could drop those medications from preferred formularies, shift them to tiers with higher patient cost-sharing, or increase pressure to substitute drugs prescribed by a patient’s physician. For patients whose conditions are stable on a specific therapy, a forced switch for insurance rather than medical reasons can disrupt treatment and risk health outcomes.

The economic stakes are substantial. Maryland’s biopharmaceutical sector supports more than 112,000 jobs and $37.2 billion in economic output, according to the Maryland Tech Council. Direct industry jobs average $167,457 in annual compensation — more than twice the average state wage.

Life sciences companies evaluating where to locate research, manufacturing, and commercialization operations weigh talent and infrastructure against regulatory risk. Policies that alter reimbursement structures or limit market viability can chill investment, particularly for early-stage and mid-sized firms that drive much of the state’s innovation economy.